Page 18 - hypertension_newsletter

REFLECTIONS
Hypertension
Hypertension Global Newsletter #10 2026

drug discovery. Tools like AlphaFold and in silico “digital Potential for artificial intelligence to inform treatment
twins” are accelerating protein-ligand interaction modeling decision-making for treatment personalization. Hypertension
and allowing researchers to simulate trial outcomes on virtual
patients, significantly reducing the time, sample size, and
costs required to bring new CV drugs to market.

This review highlights how AI is poised to revolutionize the
entire lifecycle of CV medications, accelerating early-stage
in silico drug discovery while refining individualized dosing
at the point of care. Realizing the full clinical value of these
computational advances will require the establishment of
strict regulatory standards for algorithmic medical software.
Furthermore, developers and clinicians must collaboratively
ensure that these ML models are tested on unbiased,
external datasets so that precision pharmacotherapy can
be safely and fairly deployed without perpetuating historic
healthcare disparities.

CLICK HERE
LISTEN TO AUTHOR FRANCESCO
COSTA, MD, PHD, SUMMARISE
THE POTENTIAL USES OF AI
MODELS IN CARDIOVASCULAR CLICK HERE
PHARMACOTHERAPY (8:58). FOR THE LINK TO FULL ARTICLE

ADDITIONAL ARTICLES OF INTEREST

GUIDELINES AND REVIEWS

1. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. De Backer J, et al. Eur Heart J.
2025 Nov 14;46(43):4462-4568. Erratum in: Eur Heart J. 2026 Feb 18;47(7):812.

2. Broadening primary aldosteronism screening: Alignment across contemporary guidelines. Owei L, et al.
Hypertension. 2026 May;83(5):e26228.
3. Food as medicine for hypertension: Microbiota as mediators. Kret Z, et al. Hypertension. 2025 Oct;82(10):1569-1589.

TABLE OF CONTENTS